Add Company
Join Now

AKT Revenue and Competitors

License our Company Data API

London, UK

Location

N/A

Total Funding

NonProfit

Industry

Estimated Revenue & Valuation

  • AKT's estimated annual revenue is currently $7.5M per year.(i)
  • AKT's estimated revenue per employee is $68,182

Employee Data

  • AKT has 110 Employees.(i)
  • AKT grew their employee count by -1% last year.

AKT's People

NameTitleEmail/Phone
1
Deputy CEOReveal Email/Phone
2
Chief ExecutiveReveal Email/Phone
3
Chief ExecutiveReveal Email/Phone
4
CEOReveal Email/Phone
5
Assistant Director ServicesReveal Email/Phone
6
Director FundraisingReveal Email/Phone
7
Director FinanceReveal Email/Phone
8
Director People and OperationsReveal Email/Phone
9
Human Resources ManagerReveal Email/Phone
10
Services ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.5M819%N/AN/A
#2
$7.5M84-16%N/AN/A
#3
$35M28463%N/AN/A
#4
$15M47020%N/AN/A
#5
$1.7M3300%N/AN/A
#6
$3.5M15434%N/AN/A
#7
$7.5M219-6%N/AN/A
#8
$7.5M637%N/AN/A
#9
$5.2M37-23%N/AN/A
#10
$3.5M630%N/AN/A
Add Company

What Is AKT?

akt supports lgbtq+ young people aged 16-25 in the UK who are facing or experiencing homelessness or living in a hostile environment. We support young people into safe homes and employment, education or training, in a welcoming and open environment that celebrates lgbtq+ identities.

keywords:N/A

N/A

Total Funding

110

Number of Employees

$7.5M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AKT News

2022-04-20 - Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors

The AKT kinases have emerged as promising therapeutic targets in oncology and both allosteric and ATP-competitive AKT inhibitors have...

2022-04-17 - BDH2 promotes apoptosis and autophagy of lung ...

Phosphorylation of AKT and mTOR in lung adenocarcinoma cells were reduced by BDH2 over-expression. In conclusion, BDH2 functioned as a tumor...

2022-04-17 - An effective AKT inhibitor-PARP inhibitor combination therapy ...

PI3K/AKT pathway inhibitors have been proposed to synergize with PARP inhibition to slow tumor growth, but the exact molecular mechanisms...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.5M110-10%N/A
#2
$16M110-1%N/A
#3
$15M1107%N/A
#4
$22.4M110-21%N/A
#5
$29.7M11028%N/A